(Q37686066)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Advances in immunosuppression for renal transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Antoine Durrbach

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Severine Beaudreuil

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Antoine Jacquet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Bernard Charpentier

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

2 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Nephrology

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

160-167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125095%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrneph.2009.233

17 January 2020

exact match

0 references

cites work

Cutting edge: protein kinase C beta expression is critical for export of Il-2 from T cells

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Cancer risk associated with ATG/OKT3 in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

The tyrosine kinase activity of p56lck is increased in human T cells activated via CD2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Targeting additional costimulatory pathways: a subtle role for CD2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Effects of anti-CD2 monoclonal antibody: CD2- and CD95-mediated apoptosis of human peripheral T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

A role for CD2 antibodies (BTI-322 and its humanized form) in the in vivo elimination of human T lymphocytes infiltrating an allogeneic human skin graft in SCID mice: an Fcgamma receptor-related mechanism involving co-injected human NK cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Alefacept treatment for refractory chronic extensive GVHD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

The immunological synapse.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

31 March 2020

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Costimulation blockade with belatacept in renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

When ligand becomes receptor--tolerance via B7 signaling on DCs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

CTLA-4-Ig regulates tryptophan catabolism in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

31 March 2020

12 December 2020

T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

The PKC gene module: molecular biosystematics to resolve its T cell functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Protein kinase C and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Emerging and diverse roles of protein kinase C in immune cell signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Defective IgG2a/2b class switching in PKC alpha-/- mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Protein kinase C theta affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Crucial importance of PKC-beta(I) in LFA-1-mediated locomotion of activated T cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

T-cell fate and function: PKC-theta and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Selective modulation of protein kinase C-theta during T-cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

What's next in the pipeline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Immunosuppressive strategies in transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Interleukin 2 and its receptors: recent advances and new immunological functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

JAK/STAT signaling by cytokine receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

The role of Jak3 in lymphoid development, activation, and signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Cytokines and their role in lymphoid development, differentiation and homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Jaks and STATs: biological implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

A new modality for immunosuppression: targeting the JAK/STAT pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Defective lymphoid development in mice lacking Jak3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Developmental defects of lymphoid cells in Jak3 kinase-deficient mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Tyrphostins. II. Heterocyclic and .alpha.-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Suppression of primary T-cell responses and induction of alloantigen-specific hyporesponsiveness in vitro by the Janus kinase inhibitor tyrphostin AG490

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Overcoming a positive crossmatch in living-donor kidney transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Long-term results of ABO-incompatible living kidney transplantation: a single-center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Antibody-mediated rejection in renal allografts: lessons from pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Humoral theory of transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

B cell memory and the long-lived plasma cell

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Humoral immunity due to long-lived plasma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Delayed lymphoid repopulation with defects in IL-4-driven responses produced by inactivation of NF-ATc

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

The NF-kappa B and I kappa B proteins: new discoveries and insights

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

NF-kappa B: a lesson in family values

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Inhibition of NF-kappaB-dependent T cell activation abrogates acute allograft rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

A phase 2 study of bortezomib in relapsed, refractory myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Abrogation of anti-HLA antibodies via proteasome inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Antibody-mediated renal allograft rejection: diagnosis and pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

How I treat paroxysmal nocturnal hemoglobinuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.233

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

31 March 2020

1 reference

12 December 2020

Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation

1 reference

12 December 2020

Biology of the interleukin-2 receptor

1 reference

12 December 2020

Transplantation tolerance induced by CTLA4-Ig

1 reference

12 December 2020

A novel mechanism of CD4 lymphocyte depletion involves effects of HIV on resting lymphocytes: induction of lymph node homing and apoptosis upon secondary signaling through homing receptors

1 reference

12 December 2020

Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice

1 reference

12 December 2020

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma

1 reference

12 December 2020

Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg

1 reference

12 December 2020

Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease

1 reference

12 December 2020

Caspase-independent cell death induced by anti-CD2 or staurosporine in activated human peripheral T lymphocytes

1 reference

12 December 2020

Role of proteasomes in T cell activation and proliferation

1 reference

12 December 2020

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

1 reference

12 December 2020

Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15

1 reference

12 December 2020

Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice

1 reference

12 December 2020

CD2-induced apoptosis in activated human peripheral T cells: a Fas-independent pathway that requires early protein tyrosine phosphorylation

1 reference

12 December 2020

Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum

1 reference

12 December 2020

IL-2 knockout recipient mice reject islet cell allografts

1 reference

12 December 2020

Mitogenic CD2 monoclonal antibody pairs predispose peripheral T cells to undergo apoptosis on interaction with a third CD2 monoclonal antibody

1 reference

12 December 2020

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)

1 reference

12 December 2020